Euro
USD
British Pound
NULL
Product Description
Camidanlumab Tesirine (IL2RA) Antibody, Monoclonal | 10-866 | ProSci
Host: N/A
Reactivity: N/A
Homology: N/A
Immunogen: Homo sapiens / IL2RA [Homo sapiens]
Research Area: Drug Analogues
Tested Application: N/A
Application: N/A
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: >95%
Clonality: Monoclonal
Clone: N/A
Isotype: IgG1-kappa
Conjugate: Unconjugated
Physical State: N/A
Buffer: PBS buffer pH7.5
Concentration: N/A
Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.
Alternate Name: ADCT-301, HuMax-TAC-ADC
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Camidanlumab tesirine (ADCT-301) is an antibody-drug conjugate (ADC) combining Genmab’s HuMax®-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. Camidanlumab tesirine targets CD25, which is expressed on a variety of hematological tumors and shows limited expression on normal tissues, except for regulatory T cells (Tregs) , which are known to be immunosuppressive. Camidanlumab tesirine is in development under an agreement between Genmab and ADC Therapeutics, under which Genmab owns 25% of the product rights.
